Your session is about to expire
What is Zontivity
VorapaxarThe Generic name of this drug
Treatment SummaryVorapaxar is a drug used to reduce the risk of blood clots in people with a history of heart attack or peripheral arterial disease. It works by blocking a protein called protease activated receptor (PAR-1), which is found on platelets, and prevents them from sticking together and forming clots.
Zontivityis the brand name
Zontivity Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zontivity
Vorapaxar
2014
3
Approved as Treatment by the FDA
Vorapaxar, otherwise called Zontivity, is approved by the FDA for 5 uses which include Peripheral Arterial Disease (PAD) and Heart Attack .Peripheral Arterial Disease (PAD)
Heart Attack
prophylaxis of cardiovascular event
Cardiovascular Events
Peripheral Arterial Disease
Effectiveness
How Zontivity works in the bodyVorapaxar prevents blood clots by blocking a protein that responds to thrombin, a substance in the blood that helps create blood clots. Vorapaxar does this by stopping the protein from responding to thrombin and blocking platelet aggregation. It does not affect platelets when they are exposed to other substances like collagen or adenosine diphosphate.
When to interrupt dosage
The suggested dosage of Zontivity is contingent upon the specified condition, including Peripheral Arterial Disease, Cardiovascular Events and prophylaxis of cardiovascular event. The amount of dosage depends upon the method of delivery, as outlined in the table below.Condition
Dosage
Administration
prophylaxis of cardiovascular event
2.08 mg, , 2.5 mg
Tablet, film coated, , Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Peripheral Arterial Disease
2.08 mg, , 2.5 mg
Tablet, film coated, , Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Heart Attack
2.08 mg, , 2.5 mg
Tablet, film coated, , Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Cardiovascular Events
2.08 mg, , 2.5 mg
Tablet, film coated, , Oral, Tablet, film coated - Oral, Tablet, Tablet - Oral
Warnings
Zontivity has four contraindications, and it should not be consumed in combination with the conditions described in the table below.Zontivity ContraindicationsCondition
Risk Level
Notes
Hemorrhage
Do Not Combine
Stroke
Do Not Combine
Transient Ischemic Attack (TIA)
Do Not Combine
Brain Hemorrhage
Do Not Combine
Common Zontivity Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with (R)-warfarin.
(S)-Warfarin
Major
The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with (S)-Warfarin.
4-hydroxycoumarin
Major
The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with 4-hydroxycoumarin.
Abciximab
Major
The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Abciximab.
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Vorapaxar.
Zontivity Toxicity & Overdose RiskVorapaxar may increase the risk of bleeding and brain bleeding, so it is not recommended for those who have had strokes, mini-strokes, brain bleeds, or active bleeding from a peptic ulcer. There are not enough studies to know if vorapaxar is safe for pregnant women or for breastfeeding mothers, but animal studies suggest that there is a low risk of fetal toxicity. It is also unknown if vorapaxar or its byproducts can be found in human milk.
Zontivity Novel Uses: Which Conditions Have a Clinical Trial Featuring Zontivity?
104 active clinical trials are currently in progress to investigate the potential of Zontivity to alleviate Peripheral Arterial Disease, Heart Attack and avert cardiovascular events.Condition
Clinical Trials
Trial Phases
Peripheral Arterial Disease
40 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Phase 1, Early Phase 1
Cardiovascular Events
5 Actively Recruiting
Not Applicable
Heart Attack
26 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 2, Early Phase 1, Phase 3
prophylaxis of cardiovascular event
0 Actively Recruiting
Zontivity Reviews: What are patients saying about Zontivity?
5Patient Review
6/9/20154.7Patient Review
9/22/2017Patient Q&A Section about zontivity
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Zontivity used for?
"Vorapaxar prevents heart attacks and strokes by blocking platelets from forming blood clots."
Answered by AI
Is vorapaxar FDA approved?
"The FDA has approved ZONTIVITY for the reduction of thrombotic cardiovascular events in patients with a history of heart attack or peripheral arterial disease. driven by an 18 percent relative risk reduction in MI [5.4 percent vs. first stroke [1.2 percent vs."
Answered by AI
Is Zontivity a blood thinner?
"Zontivity is a medication designed to reduce the formation of blood clots. By decreasing the formation of blood clots, Zontivity decreases the risk of heart attack and stroke, the FDA stated."
Answered by AI
Who manufactures Zontivity?
"ZONTIVITY tablets, 2.08 mg vorapaxar, are oval-shaped, yellow, film-coated tablets with “351” on one side and the Merck logo on the other."
Answered by AI